ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
Zomedica Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026
- Market cap
- $77.40M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
67.7%
Operating margin
-263.4%
Net margin
-255.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.4% | +19.2% | – | – | |
| Gross profit | +13.6% | +17.2% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -158.4% | -63.6% | -52.6% | |
| Return on assets | – | -48.1% | -49.0% | |
| Current ratio | 4.83 | 31.48 | 6.78 | |
| Interest coverage | – | -22903.0× | – | |
| Inventory turnover | – | – | 2.0× | |
| Capex to revenue | – | – | 1.8% | |
| Diluted shares | 80M | 364M | 980M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Zomedica generated $83.20M from operations and spent $18.05M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$83.20M
Used
$18.05M
Capital expenditure$18.05M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-255.6%
×Asset turnover0.19×
×Equity multiplier1.08×
=Return on equity, FY2025-52.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -255.6% | 0.19× | 1.08× | -52.6% |
| FY2024 | -172.2% | 0.12× | 1.06× | -21.6% |
| FY2023 | -137.1% | 0.09× | 1.05× | -13.6% |
| FY2022 | -89.9% | 0.07× | 1.04× | -6.3% |
| FY2021 | -444.8% | 0.02× | 1.08× | -11.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$81.86M
- Cash generatingOperating cash flow above zero-$17.65M
- Return on assets improvedROA up on the prior year-18.6% → -39.5%
- Earnings backed by cashOperating cash flow above net income-$17.65M vs -$81.86M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.76 → 6.78
- No dilutionShare count did not rise980M → 980M
- Gross margin improvedGross margin up on the prior year69.95% → 67.68%
- More efficientAsset turnover rose0.11 → 0.15